Article Sidebar

PDF
Date Published: 25/02/2022
Abstract Views: 1153
Views PDF: 422
DOI: https://doi.org/10.51298/vmj.v510i1.1946
Issue
Vol. 510 No. 1 (2022)
Section
Các bài báo
How to Cite
Đức Long, P., Thị Anh Đào, L. ., & Quang Vinh, T. . (2022). DETERMINE THE PREDICTED VALUE OF CA125, HE4 AND ROMA TESTS IN DIAGNOSE OVARIAN CANCER AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL. Vietnam Medical Journal, 510(1). https://doi.org/10.51298/vmj.v510i1.1946

DETERMINE THE PREDICTED VALUE OF CA125, HE4 AND ROMA TESTS IN DIAGNOSE OVARIAN CANCER AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL

Phan Đức Long1, Lê Thị Anh Đào2,, Trương Quang Vinh3
1 General Hospital of Agricultural
2 Hanoi Medical University
3 University of Medicine and Pharmacy, Vietnam National University, Hanoi

Main Article Content

Abstract

Diagnosis of ovarian cancer is often late and difficult, due to the lack of specific signs. Ultrasounds or IRM images can not diagnose ovarian cancer as well. CA 125 and HE 4 tests and ROMA tests have been shown to predict ovarian cancer risk. The study aims to: Determine the predicted value of CA125, HE4 and ROMA tests in diagnose ovarian cancer in the population of ovarian tumor patients undergoing surgery at Hanoi Obstetrics and Gynecology hospital in 2018-2019. This is a cross sectional study has implemented from August 2018 to June 2019. Patients with ovarian tumors have been tested CA 125, HE4 and ROMA test before surgery.  Based on the pathology’s results after surgery to assess the sensitivity and specificity of these 3 tests. Results: Of the 209 patients with ovarian cancer, 33 had ovarian cancer. The sensitivity and specificity of CA125 in ovarian carcinoma are 88%, 70%. The sensitivity and specificity of HE4 in UTBMBT are 64% and 96.6%. The sensitivity and specificity of ROMA test in UTBMBT are 92%, specificity ROMA = 55.32%. Conclusions: CA 125 and HE4  have predictive values in diagnosing ovarian cancer, the combination between CA 125 and HE4 is better than single test.

Article Details

Keywords

CA 125, HE4, ROMA test

References

1. Pearce C.L., Stram D.O., Ness R.B. et al. (2015). Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiol Biomarkers & Prev, 24(4), 671 LP – 676.
2. Ferlay J., Soerjomataram I., Dikshit R. et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer, 136(5), E359-86.
3. Li K., Hüsing A., Fortner R.T. et al. (2015). An epidemiologic risk prediction model for ovarian cancer in Europe: The EPIC study. Br J Cancer, 112(7), 1257–1265.
4. LaVigne K., Dao F., Abu–Rustum N. et al. (2017), HE4 is a biomarker for newly diagnosed and recurrent high - grade serous ovarian cancer with normal CA 125 values.
5. Moore R.G., McMeekin D.S., Brown A.K. et al. (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112(1), 40–6.
6. Aslam N., Banerjee S., Carr J. V et al. (2000). Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol, 96(1), 75–80.
7. Piek J.M.J., van Diest P.J., Verheijen R.H.M. (2008). Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol, 622, 79–87.
8. Dikmen Z.G., Colak A., Dogan P. et al. (2015). Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. Eur J Gynaecol Oncol, 36(4), 457–462.
9. Huy N.V.Q., Van Khoa V., Tam L.M. et al. (2018). Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecol Oncol reports, 25, 110–114.